VRDN Viridian Therapeutics Inc

$VRDN Most likely going to see neck-and-neck data against ARGX-213. Now Argenx is under threat right alongside Amgen. Wouldn't be surprised if this turns into Moderna 2.0. Time will tell

$VRDN Enspryng being first to market subQ does nothing more than pave the way for elagrobart. Just like Immunovant’s success in RA expanded the FcRn market 4x while Viridian was right behind them. 1.5M shares were covered during the recent dip. Those who panic sold lost again. Guys, there’s honestly nothing to debate here at this stage because there’s simply nothing left to argue. It’s a done deal. Enjoy the ride.

$VRDN Love the relative strength here… sky is falling elsewhere and this is down less than 1%

$VRDN Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.81 down -138.24% YoY • Reported revenue of $25.75M down -63.51% YoY

$VRDN Wonder who wants to dominate Chronic TED? 75% of the market and the only treatment approved with positive clinical results. COme and get it.....

$VRDN spotlight 🔎 Strong recovery on the 2-hour chart, with price pushing into the $29–30 area—a prior trading zone that could act as resistance. Watching whether it can hold above $28 and build a base. Below that, $25–26 is the next support area to monitor. Extended move here; chasing raises the risk. Biotech stocks can move sharply on news. Trade idea only—not personalized advice. #Biotech #SwingTrading

$VRDN Stifel raised its Q4 2026 revenue estimate to $53 million (from $19 million) and its full-year 2027 revenue estimate to $290 million (from $211 million)

$VRDN Up those price targets and crank up the IB calls... these guys wont be stand alone thru 2027 IMO

Stifel⬆️ $VRDN's PT to $43 from $40, reiterated Buy and said--The first full quarter for the Lumvoa launch in TED delivered a strong beat $24.7MM vs. $5MM. [ $AMGN IMVT ROIV RHHBY] Perhaps more importantly, demand metrics including >100 patients on therapy at quarter-end imply more rapid uptake than anticipated. While it's still early, maintenance of this trajectory implies that Lumvoa is well on its way to achieving meaningful share of the largely incident market based on its broader label and more convenient course vs. Tepezza. We expect numbers to come up for 4Q26 and 2027 and have updated our model based on a faster ramp--our estimates for 4Q26 go to $53MM from $19MM and 2027 to $290MM from $211MM. Meanwhile, the elegrobart subcu BLA filing is on track for 1Q27. Beyond TED, an FcRn franchise update is on track before YE while TSHR mAb VRDN-292 will enter Ph1 in Graves' patients.

$VRDN reported earnings before the open today. GAAP EPS beat estimates: -$0.81 vs. -$1.02 expected, according to Stock Meadow.

$VRDN spent 37 sessions under its 200-day average and closed above it today. The last close above it was Aug 26. The score is a 2 for now, Below Average, #118 of 296 in its industry.

$VRDN how do you guys feel about the “Enspryng” product from Roche that has been FDA approved Is it gonna hurt Viridian or not? How so?

$VRDN just want to get your ideas the advantage Lumvoa has over Tepezza? Is it going to take share away from it or both can grow in their market. What's the expected sales for Lumvoa for Q3?

Ticker SCAG had huge news today: Scage Future Enters into Strategic Cooperation Agreement with China Huaye Group SCAG has only 1.3 million shares float - Chinese - Watch it 👀🚀 $VRDN $SSMR $PTN 9d